Orthocell in Murdoch, Western Australia | Medical and health

Orthocell

Locality: Murdoch, Western Australia

Phone: +61 8 9360 2888

Address: Building 191 Murdoch University South Street, 6150 Murdoch, WA, Australia

Website: https://www.orthocell.com.au

Likes: 172

Add/Update information

Reviews

Tags

• Medical and health

25.01.2022 Investor presentation Orthocell (ASX $OCC) executives are meeting with an important group of current and potential investors today. Our latest Investor Presentation contains a comprehensive update of Orthocell’s regenerative medicine product portfolio, including a summary of key clinical, regulatory and commercial milestones.... Our team is pursuing a total addressable market valued at US$17billion per annum, and remain committed to bringing better treatments to the hands of clinicians to address complex musculoskeletal disorders. View the presentation here http://bit.ly/OCC_Presentation #regenerativemedicine #innovation #biotech #pharma

25.01.2022 NEW US PATENT Orthocell has received a new US divisional patent for our CelGro product, titled Method for Producing a Collagen Membrane and Uses Thereof. This patent provides additional important intellectual property (IP) to protect our CelGro platform for soft tissue regeneration and repair applications.... Building a strong IP portfolio is a foundational requirement for successful global commercialisation of our products particularly when you consider we are pursuing a global addressable market for CelGro which exceeds >US$10bn. Read today’s ASX release here http://bit.ly/OCC_USPatent $OCC #regenerativemedicine #innovation #biotech #pharma #striate+

25.01.2022 Quarterly Report Our latest quarterly report for the period ended 30 June 2020 was released to the ASX this evening. Orthocell is in a strong cash position of >$20m and approaching significant milestones in the development and commercialisation of CelGro and Ortho-ATI.... Recent achievements include our submission of a US FDA regulatory application for CelGro for dental guided bone and soft tissue regeneration; submission of a AUS TGA regulatory application for CelGro for nerve regeneration; completion of recruitment to our randomised controlled clinical trial of Ortho-ATI; and positive results for our Annual Quality Study, which showed an 87.5% patient satisfaction rating using Ortho-ATI cell therapy for the treatment of chronic tendon injuries. Read the full report here https://bit.ly/OCCQuarterlyJune

25.01.2022 IN THE NEWS The Market Herald has covered today's announcement of positive data for #Orthocell's CelGro for nerve regeneration program. See it here https://bit.ly/OCC_MH_Nerve

25.01.2022 We are delighted to announce that Orthocell claimed the top spot in Pitch@Palace on Friday night in Perth. CEO, Paul Anderson participated in a series of workshops, mentoring sessions and pitches last week, which culminated in a final 3 minute pitch at Government House on Friday night. Dignitaries included Prince Andrew Duke of York, Julie Bishop, Kim Beazley as well as a number of well known identities from corporate Australia. Pitch@Palace is a global movement started by the British royal family, which aims to amplify the work of entrepreneurs around the world and deepen their global impact. #pitchatpalace #entrepreneur https://startupnews.com.au//was-orthocell-wins-a-place-in/

24.01.2022 Orthocell ($OCC) is pleased to announce that we have received confirmation from the FDA that the proposed CelGro nerve regeneration animal study protocol meets requirements to support the near term 510(k) submission. We have now accelerated ethics applications to commence the study in Q1 CY2020. With the safety and efficacy of the CelGro nerve repair product established, Orthocell is accelerating its regulatory program to gain approval in the US, EU and AUS." - Orthocell Managing Director Paul Anderson. View the ASX announcement via: https://www.orthocell.com.au/asx-announcements-3

24.01.2022 IN THE NEWS | Reach Markets has published an article featuring Orthocell, following the recent participation of $OCC MD, Paul Anderson, in the 'Meet the CEOs' event. Take a look

23.01.2022 Protecting our intellectual property has always been a key part of our commercialisation strategy at Orthocell. Securing patents helps to prevent others from copying, manufacturing and selling our products and in doing so, supports our collective investment in ethical innovation. Speaking of which We have now secured more crucial patents to protect our CelGro platform product in Canada and Japan in addition to previously granted patents in the US, Canada, Europe, China,... Japan, Singapore, Australia and New Zealand. This is a great achievement, further validating our IP strategy. Read the full announcement http://bit.ly/OCC_Patents

23.01.2022 Finance News Network covered Orthocells ($OCC) latest clinical trial results explaining that a review of patients who completed the trial confirmed all patients achieved a successful [rotatorcuff] tendon repair with no revision surgeries reported. Watch the full update via the Finance News Network. Our latest ASX announcement describing the results of the clinical trial can be found via https://www.orthocell.com.au/asx-announcements-3.

23.01.2022 Novel treatment Our goal at Orthocell is to unlock the body’s potential to regenerate and heal. Now we have combined the use of our lead products, Ortho-ATI and CelGro, to develop a novel surgical treatment for tendon repair. ... Led by respected key opinion leaders orthopaedic hip specialist surgeon, Dr John M O’Donnell, and sports and exercise doctor, A/Professor Jane Fitzpatrick Ortho-ATI and CelGro were used to treat a 63 year old patient who required surgical repair of a large degenerate tear of the gluteal medius tendon. The patient case study was published in the International Journal of Case Reports. Learn more in today’s ASX release http://bit.ly/OCC_NovelTreatment

22.01.2022 Let’s talk about Ortho-ATI Orthocell’s advanced cell therapy that directly addresses the root cause of degenerate tendon injury. It works like this Orthocell harvests a patient’s own cells from the same tissue that requires repair... A piece of healthy tissue is collected by a surgeon and transported to the Orthocell laboratory, where the cells are grown Only cells of the highest purity and potency are returned to the patient, ensuring high quality tissue repair Orthocell has now treated more than 500 patients and stories like Dean Allison’s make it all worthwhile Before having the treatment I underwent three lots of surgery and had pretty much accepted I would never be 100% again. I have experienced a 100% recovery, I am pain-free, able to exercise and run without issue. I have been able to continue my job as a tactical flight officer. #regenerativemedicine #celltherapy #biotech #pharma #health #ASX

22.01.2022 Orthocell Board update Orthocell has today welcomed Matt Callahan back to the Board, in his previously held role of Executive Director, following a temporary leave of absence. Matt is an invaluable part of our advisory team and his return comes at an excellent time, as we prepare for major regulatory approvals and clinical milestones in the year ahead.... Read todays announcement here http://bit.ly/OCCMatt

22.01.2022 Orthocells Ortho-ATI treatment can be used in both pre-surgical and post-surgical applications and is at the forefront of a growing market opportunity, estimated to be worth more than US$7.7bn. Today, we have announced the completion of the patient recruitment phase of our randomised controlled trial designed to assess the effectiveness of Ortho-ATI for the treatment of rotator cuff tendinopathy and tear. This study is being done in collaboration with DePuy Synthes Product...s, part of the Johnson & Johnson Medical Devices Companies. Read the ASX release here https://bit.ly/OCC_RecruitmentComplete

21.01.2022 Orthocell update Strengthening and expanding the intellectual property (IP) footprint of our products at Orthocell is paramount, particularly as we enter some of the influential healthcare markets in the world. Orthocell was recently awarded United States Divisional Trade Mark Registration for our Ortho-ATI cell therapy for the treatment of chronic tendon injuries. This will remain in force for an initial period of 10 years and may be renewed for successive periods of ...10 years thereafter. We are delighted to receive this important trade mark, which complements our strong intellectual property portfolio and ongoing efforts to bring this exciting technology into the US market. #intellectualproperty #regenerativemedicine #innovation #biotech #medtech

21.01.2022 CelGro Bone Regeneration Orthocell has today announced that positive pre-clinical and clinical results for the use of CelGro in enhancing repair of bone defects has been published in the highly regarded ‘Tissue Engineering’ Journal. The paper, ‘Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’, further enhances our base of evidence that CelGro out-performs current market leading products in facilitating bone growth in oral maxillofac...ial reconstructive surgery and orthopedic applications. See today’s ASX release here http://bit.ly/OCC_BoneUpdate #innovation #biotech #pharma #regenerativemedicine

20.01.2022 Guess whats headlining Stockhead today? News that Perth is becoming one of Australias top life sciences hubs. WA Deputy Premier and Health Minister, The Hon. Roger Cook MLA, had this to say: We have a fantastic opportunity to further support our local health and medical life sciences industry which continues to deliver world-leading innovations that improve health outcomes for people in our state and globally.... Orthocell was highlighted for proving its technology works and tripling its share price in the past year Take a look http://bit.ly/OCCStockhead

20.01.2022 One of the primary pillars of our research and development strategy at Orthocell is to work with highly regarded clinical key opinion leaders, and to support ongoing education. This week, two of our leading clinical investigators, Prof Ming Hao Zheng and Prof Allan Wang, joined forces to share a presentation in Mandurah near Perth. They provided insight into the science of Ortho-ATI; examined clinical data; and shared evidence of its use and impact in clinical practice too.... Among the audience were physiotherapists, occupational physicians and general practitioners. Thank you to all who attended - we look forward to collaborating with more clinical practitioners in future to extend the reach of this life-changing cell therapy.

19.01.2022 Recent clinical trial results showed an 89% success rate using our novel CelGro tendon regeneration technology for rotator cuff tendon injuries. Read the article published in Small Caps this week via: http://bit.ly/2LuBEMF.

18.01.2022 Dr Boreham’s Crucible Orthocell was featured in Dr Boreham’s Crucible this week, a widely read and respected column by small cap analyst and business journalist, Tim Boreham. The column first appeared in Biotech Daily and was republished on Stockhead too.... Take a look http://bit.ly/OCC_TimBoreham

18.01.2022 Orthocell’s regenerative medicine portfolio is innovative at its core. Regenerative medicine unlocks the body’s ability to self-repair or replace injured or diseased tissue. It is an evolving and exciting area of research. Right now, Orthocell is manufacturing cell therapies for cartilage and tendon repair, together with a bio-active collagen scaffold too.... Already, our therapies are having a positive impact on the lives of patients and empowering our partnering clinicians to optimise their treatments. Take a closer look bit.ly/OCCProducts

17.01.2022 Proactive Investors Orthocell MD, Paul Anderson, has shared our latest news with Andrew Scott from Proactive Investors, as part of a seven minute recorded interview. He spoke about Orthocell’s product portfolio, promising clinical data, regulatory milestones and commercial progress together with a closer look inside our labs at the Orthocell HQ in Perth.... Take a look http://bit.ly/OCC_ProactiveInvestorsSep

17.01.2022 Patient film Today were launching a new film series that captures patient and clinician insights from the frontline, as part of Orthocells research and development. The first film shares the story of Daniel Kerr, a well-known AFL star who played 220 games for the West Coast Eagles between 2001 and 2013. ... At the age of 28, he suffered a complete hamstring rupture, which doctors described as a career ending injury. After exhausting traditional surgical and non-surgical treatments, he finally found Ortho-ATI. Daniels experience is a poignant example of the very real human impact we are starting to see, as a result of the innovation we are leading at Orthocell. Today we have also announced results from our Annual Quality Survey on the on the ASX, showing an 87.5% success rate using Ortho-ATI for the treatment of chronic tendon injuries in the shoulder, elbow, hip, knee and ankle. Watch and share Daniels story now https://bit.ly/OCC_DanielKerr #regenerativemedicine #precisionmedicine #biotech #sportsmedicine #innovation

17.01.2022 IN THE NEWS | $OCC MD, Paul Anderson, spoke on the Bulls N' Bears program with Matt Birney recently

17.01.2022 Orthocell patient case study Leading sports doctors have published a case study profiling the recovery of a 77 year old Ortho-ATI patient Orthocells minimally invasive cell therapy to regenerate tendons. After suffering chronic shoulder pain for over three years, with function declining to around 20 percent, Ortho-ATI helped to restore his ability to play golf, do the gardening and even push-ups.... He was completely symptom free twelve months later further evidence that Ortho-ATI is a breakthrough in regenerative medicine. Take a look at the case study published in the International Journal of Case Reports https://bit.ly/OCC_OrthoATICaseReport

16.01.2022 The bright brains behind Orthocells technology are the kind of people who often wear a few hats especially when it comes to research, because innovation is in their DNA. Our Co-Founder and Chief Scientific Officer, Professor Ming-Hao Zheng, is also the Dean of The University of Western Australias (UWA) Faculty of Health and Medical Sciences, and today, a recent study coordinated by UWA in partnership with Fiona Stanley Hospital is making headlines. The study was published... in BMJ Journals and found obese patients undergo knee replacements around eight years earlier than those who are a regular weight. The team of scientists found extra body weight caused a pathological change of the knee that had not been understood before, called horizontal fissuring where the area between the cartilage and bone breaks down. This type of impactful evidence-based research is critical for supporting the growing need for Orthocells products for restoring mobility, function and performance. So hats off to Professor Zheng and this research team for increasing our knowledge base. Take a look at the original article published by UWA here http://www.news.uwa.edu.au//obesity-linked-earlier-need-kn

16.01.2022 In the media Want to get to know our Managing Director Paul Anderson? Take a look at this Q&A published by StockPal today. Spoiler alert Orthocells work is very close to his heart:... the most fulfilling experience is to see our products make profound impacts on peoples lives and this has been and is an absolute privilege beyond my expectations. Take a look https://bit.ly/OCC_Media_PA

15.01.2022 Did you know that our CelGro device was originally inspired by nature? It all started on a beach. Our Co-Founder and Chief Scientific Officer, Professor Ming Hao Zheng, was fascinated by the loosely arranged bundles that make up the structure of a sea sponge. Soon after, he developed a collagen medical device that mimicked these interconnected particles.... CelGro is now used to facilitate tissue repair in a variety of orthopaedic, reconstructive and surgical applications.

15.01.2022 Positive clinical data Orthocell has today released positive clinical data for our CelGro for nerve program, which shows nerve repair with CelGro resulted in long term predictable and consistent restoration of arm and hand function. Key outcomes for patients included:... All quadriplegic patients regained voluntary movement of impaired or paralysed upper limbs within 12 months 17 of 19 (89%) nerve repairs restored voluntary movement to previously paralysed muscles CelGro’s global addressable market in peripheral nerve repair is estimated to be worth more than US$7.5 billion per annum, with approximately 3,000,000 procedures that could use the device completed each year so we hope to have an opportunity to help many more people in future. Read today’s announcement here https://bit.ly/OCC_NerveData

15.01.2022 CASE REPORT: Adrian Walsh (43) was diagnosed with quadriplegia after he broke his neck in a mountain bike accident in June 2017. He retained some movement in his elbows and upper arms, but his hands, torso, and legs were paralysed and his arms didnt have enough strength to use a wheelchair on his own. Since his treatment with CelGro, Adrians improved arm strength and function has given him more independence and the ability to take on new challenges. Watch Adrians story below and read more about it here https://www.orthocell.com.au/patientvideo. Access the media release reporting the CelGro nerve regeneration interim results via https://www.orthocell.com.au/asx-announcements-3 https://youtu.be/40uXwWQsehc

15.01.2022 Small Caps covers Orthocells recent announcement of positive interim clinical results for the use of CelGro for enhancing the repair of peripheral nerves where 96% of nerve repairs restored voluntary movement to previously paralysed muscles. Read the full story below.

14.01.2022 Orthocell update Dental implants are a rapidly growing area of orthodontic treatment. Did you know that approximately 4.3 million procedures require dental membranes each year? Or that the market is worth approximately US$1 billion per annum?... Today, Orthocell has announced that it has completed a submission to the US Food and Drug Administration (FDA) seeking 510(k) clearance for marketing CelGro for dental guided bone and soft tissue regeneration. An important step forward. Read the announcement here https://bit.ly/OCC_510K

14.01.2022 Reimbursement milestone More good news for our CelGro dental program (recently re-branded Striate+) today. We have received notification from the Australian Government Department of Health, that the Prostheses List Advisory Committee has recommended the Minister of Health ratify its inclusion on the Prostheses List (PL). ... Inclusion on the prothesis list enables reimbursement from private insurers for Striate +, made possible by our recent Australian TGA approval and clinical data. See today’s ASX release here https://bit.ly/OCC_Reimbursement

14.01.2022 NEW EXECUTIVE DIRECTOR Orthocell is pleased to welcome an experienced Executive Director to the Board, Leslie Wise, JD. Leslie has over 20 years of specialist experience working in US reimbursement, life science, and medtech fields, and is ideally suited to support the next phase of our Companys development particularly as we prepare to enter the US healthcare market.... Leslie has honed her skills in reimbursement, value evidence generation, clinical research strategy, regulatory and payer experience and has worked with some of the most respected pharmaceutical and medtech companies in the world. Take a look at todays ASX announcement here https://bit.ly/OCC_LeslieWise

13.01.2022 Orthocell has today published a comprehensive update as part of its latest Quarterly Report packed full of good news. Highlights from the quarter have included completing the US FDA regulatory study demonstrating successful bone growth using CelGro; approval to commence the CelGro nerve regeneration US regulatory (FDA) animal study expected shortly; progressing the randomised controlled clinical trial of Ortho-ATI versus corticosteroid injection (in partnership with DePu...y Synthes Products, Inc., part of the Johnson & Johnson Medical Device Companies); publication of a successful Rotator Cuff Regeneration case study; and new patents granted for CelGro technology in Canada and Japan. We were also fortunate to receive an A$2.9m R&D tax incentive refund and remain in a strong cash position of >$20m to meet our near term goals. Read the Quarterly Report here https://bit.ly/OCC_Quarterly

11.01.2022 This fortnight we have been actively sharing the $OCC story. This is our MD, Paul Anderson, speaking with shareholders and supporters at an event hosted in conjunction with Argonaut Securities in Perth last night. You can view our latest investor update here http://bit.ly/OCC_Preso_NEW

11.01.2022 Orthocell wins Pitch@Palace

11.01.2022 CelGro Nerve update Orthocells CelGro Nerve program is moving through important clinical and regulatory milestones. Today, we are pleased to share a positive update our collaborating clinicians have now treated 300 patients via the TGAs Special Access Scheme (SAS) for CelGro. ... CelGro Nerve is proving to have a positive impact on the lives of people who require complex nerve treatments, often with limited treatment pathways available. Just ask 43-year-old Adrian Walsh, a proud father of three who broke his neck in a mountain bike accident in June 2017. CelGro helped to improve Adrians arm strength and function, and he was proud to share his story which we think is truly incredible. Take a look http://bit.ly/OCC_AdrianWalsh

10.01.2022 IN THE NEWS Orthocell MD, Paul Anderson, appeared on Proactive today to discuss the latest clinical results in our CelGro nerve regeneration trial. Take a look https://bit.ly/OCC_PI_nerveinterview

09.01.2022 It is truly exciting that CelGro can assist with intricate surgery to repair nerve damage a complex, but potentially life-changing, treatment. Orthocell is incredibly proud to be progressing its clinical research program in partnership with world-class surgeons and patients, to understand exactly how CelGro performs to improve the quality and ease of nerve repair. According to leading Australian orthopaedic nerve specialist, Dr Alex OBeirne, who is a principal investigat...or in our trial, CelGro has the potential to increase the strength and quality of the repair and makes surgery easier, by allowing surgeons to re-join nerves without tension. Eager to see how it works? Take a look at this animation https://bit.ly/OCC_NerveAnimation #regenerativemedicine #biotechnology #medicaldevice #pharma #innovation

09.01.2022 Orthocell update Orthocell is chasing a US$1 billion per annum market opportunity in dental restoration so todays news is definitely worth smiling about. We have just announced results of a positive US 510(k) CelGro dental bone study, reinforcing that CelGro is a superior medical device for bone and soft tissue repair.... This Study provides critical data and is a key component of the US 510(k) submission required for US market approval. Read more http://bit.ly/OCC_BoneStudy

08.01.2022 $OCC UPDATE | Delighted to report we have received a A$2.3m R&D tax incentive refund - vital funds that will continue to drive commercialisation and innovation at #Orthocell. See ASX release here https://bit.ly/2XTkRcz

07.01.2022 Community Sponsorship It is always rewarding to help people to achieve better health outcomes and see them go on to live full and active lives. One of our Ortho-ATI patients and well-known AFL player, Daniel Kerr, is one such person. He joined us on the weekend to present a sponsorship package on behalf of Orthocell to the North Beach Tigers Integrated Football Team.... The Perth Football League hosts the Integrated Competition in Western Australia and encourages the inclusion and participation of athletes with an intellectual disability in an Australian Football competition. The ethos of the league is about fairness and equality; respect and dignity; teaching individuals how to strive and succeed; how to cope with success and disappointment; and it brings people together with a common goal. Our Managing Director, Paul Anderson, and Daniel spent time speaking with the team, their parents, the team captain and coach and they kicked a footy together too. Daniel presented a football from his foundation for the best on ground player and provided a great source of inspiration for all involved. Orthocell sponsored bags and footballs for the team members, and we cant wait to continue our support in future

06.01.2022 Last week Orthocell Ltd ($OCC) was pleased to report the final results from patients who completed the CelGro tendon regeneration clinical trial showing 89%of patients return to work and recreation pain-free. Orthocell Managing Director Paul Anderson spoke with Stockhead, commenting that "we are extremely excited by the clinical follow up results indicating effectiveness of CelGro in reducing the surgical revision rate. CelGro is proving to be a breakthrough soft tissue reconstruction platform technology with positive data announced now in nerve, tendon and bone applications. http://bit.ly/31fBkYY

06.01.2022 Our Co-Founder and Chief Scientific Officer, Professor Ming Hao Zheng, last week presented as part of a webinar delivered by The City of London Dental School. He shared insight into the use of Orthocells CelGro collagen membrane for guided bone regeneration treatment, together with supporting biological, pre-clinical and clinical data. Our Company is proud to contribute to the continued professional development of clinicians in the field of dentistry. #professionaldevelopment #innovation #dental #biotech

05.01.2022 Thanks to Reach Markets for hosting our MD, Paul Anderson, at their ‘Meet the CEOs’ event yesterday. Take a look https://www.facebook.com/1960722830636973/posts/4462510253791539/?extid=CL8q143LiZcjawSF&d=n

05.01.2022 CelGro for nerve Orthocell has today announced that it has completed a submission to the Australian Therapeutic Goods Administration (TGA) seeking approval for marketing CelGro for use in peripheral nerve regeneration applications in Australia. This regulatory milestone has the potential to extend the reach and impact of this world-class treatment by making it more accessible to surgeons and ultimately patients. ... Encouragingly too, our nerve program continues to garner significant interest from clinical partners, patients, and investors. Read the ASX release here https://bit.ly/OCC_NerveTGA

04.01.2022 Orthocell ( $OCC) is pleased to announce positive interim clinical results for the use of CelGro for enhancing repair of peripheral nerves. Following surgery with CelGro, patients have regained muscle function in the affected limbs and have either ceased or significantly reduced prescription pain medication (including opioid-based medications). https://www.orthocell.com.au/asx-announcements-3

04.01.2022 SPECIAL FEATURE In today's issue of The Weekend Australian, Health Editor Natasha Robinson has written an article titled, 'Medical miracle brings limbs back to life.' Said 'miracle' is referring to Orthocell's CelGro for nerve regeneration treatment.... Natasha spent considerable time examining the science behind Orthocell's CelGro for nerve program, which included interviewing patient, Adrian Walsh; the lead surgeon in our clinical trial, Dr Alex O'Beirne; rehabilitation specialist, Jaslyn Cullen; and Orthocell Managing Director, Paul Anderson. Here is an excerpt: 'In the past, there would have been little doctors could do. But in the past few years, significant advancements in peripheral nerve surgery have given hope to quadriplegics. Now a new medical device is transforming the field further, helping to restore limb function to those who are paralysed.' Yesterday we announced positive clinical data from our CelGro for nerve trial at the 24-month post treatment mark - and we are privileged to be taking considered steps forward, with the aim of providing access to this treatment for more people like Adrian around the world. Thank you to Adrian and his young family for bravely sharing their story. Read the article here https://bit.ly/OCC_TheAustralian

03.01.2022 IN THE NEWS Proactive Investors talks CelGro: The product represents a breakthrough in soft tissue reconstruction and offers significant commercial potential in existing addressable markets of bone, tendon, nerve and cartilage, and wider applications in general surgical and soft tissue reconstructive applications. The global addressable market for CelGro is more than US$4.4 billion and growing.... Read the full article here http://bit.ly/OCC_Proactive_Celgro

03.01.2022 In The Australian Business Review Sarah-Jane Tasker reports on our CelGro interim review. Twelve months after treatment the review showed that in the quadriplegic patients, 73 per cent of nerve repairs resulted in meaningful functional recovery of affected muscles in the 12 months. Seeing one of our patients progress from no strength in his arm, and no movement in his fingers and thumb, to playing wheelchair rugby is extremely encouraging for our researchers and clinical partners, - Orthocell managing director Paul Anderson. Read the full story below. https://www.theaustralian.com.au//71ebe3964ffbb378672d5084

02.01.2022 Orthocells CelGro collagen membrane assists in strengthening the surgical repair of damaged or torn tendons to restore function and relieve pain. Current surgical repairs are performed with great skill, but unfortunately there is a high rate of failure. The repaired tendon is often weaker, due to the poor quality of the tendon tissue, and prone to re-tear. CelGro was designed with handling characteristics to assist surgeons perform reconstructive procedures, while creating a unique healing environment to improve the quality of the regenerated tendon tissue. Better quality tissue strengthens the repair and reduces the risk of re-tear. https://youtu.be/BG_TMyHur74

02.01.2022 This week Money Morning Australia covered the results of our successful CelGro tendon regeneration trial in rotator cuff tendon repair patients. Money Morning Australia covered this initial announcement earlier this year, where they noted that "the future results of the trial if positive could provide a boon for the company. And it looks like it has." Access the ASX announcement via https://www.orthocell.com.au/asx-announcements-3 for full details.

01.01.2022 Ortho-ATI was this month featured in a respected textbook released in association with The International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS), titled Surgical Techniques for Trauma and Sports Related Injuries of the Elbow. The therapy appeared in a chapter authored by Prof. Allan Wang, Dr Katherine Mackie, Dr William Breidahl and Prof. Ming Hao Zheng, and has already been downloaded over 3000 times. This signals a contribution of ...knowledge and teaching to clinicians, as we continue to develop innovative regenerative medicine treatments. Interested to take a look? A summary of the chapter explaining Ortho-ATI is available here https://bit.ly/OCC_TextBook